{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:59:53Z","timestamp":1785373193620,"version":"3.55.0"},"reference-count":66,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand\u2010alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT2is) when marketed in Europe in 2012. This study tested the feasibility of active surveillance, continuously re\u2010evaluating the UTI risk following approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This sequential cumulative cohort study emulated surveillance of UTI among type 2 diabetes patients initiating SGLT2is using Danish healthcare data (2007\u20132022). Outcomes were bacterial UTI\u2010related prescriptions and UTI\u2010related hospital contacts. Dipeptidyl peptidase\u20104 inhibitors (DPP\u20104is) and glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) were active comparators. Annual incidence rates (IRs) and propensity score weighted hazard ratios (HRs) were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The 198\u2009613 eligible initiation episodes were included. Among SGLT2is, the UTI\u2010related prescription IRs were in the range 140.9\u2013200.9 per 1000 person years, declining steadily after 2014. IRs of hospital contacts ranged between 11.8 and 21.7 per 1000 person years, initially decreasing but rising again after 2018. The earliest conclusive risk estimate was observed in 2016, indicating no increased UTI risks of interest associated with SGLT2i use. HRs for bacterial UTI\u2010related prescriptions remained under 1 over time in both comparisons, while the HR for serious UTI events varied with follow\u2010up time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study demonstrating the feasibility of continuous surveillance for evaluating real\u2010world UTI risk among SGLT2i users without aiming to establish causality. The IR of serious events was low, and stable HRs indicate no increased risk from 2016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70558","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:15:14Z","timestamp":1776226514000},"page":"2741-2755","source":"Crossref","is-referenced-by-count":0,"title":["Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium\u2010glucose cotransporter 2 inhibitor users"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-3034","authenticated-orcid":false,"given":"Haoxin","family":"Le","sequence":"first","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilsad Simay","family":"Peker","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Research Group, Department of Drug Design and Pharmacology University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas Frederic","family":"Westphal","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Brun","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Erikstrup","family":"Hallgreen","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-2860","authenticated-orcid":false,"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Research Group, Department of Drug Design and Pharmacology University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745\u20106215\u201013\u2010138"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.011"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.012809.103649"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102125.1997.05417.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613490780"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0905338"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3616"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40471\u2010017\u20100121\u20100"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2316"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010024\u201001142\u20109"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.04.012"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3182459d7d"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594770\u2010000000000\u201000000"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008034"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010015\u20100341\u20105"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5548"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010021\u201001110\u2010x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u20100011"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj\u20102020\u2010139090"},{"key":"e_1_2_11_22_1","unstructured":"Forxiga: EPAR \u2010 Public Assessment Report Committee for Medicinal Products for Human Use (CHMP) https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/forxiga-epar-public-assessment-report_en.pdf"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010159\u20104\u2010201308200\u201000007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.01.040"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005722022"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592\u2010018\u20101116\u20100"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2023.11509"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u20102169"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.910"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9120059"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20103136"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2021.12.005"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14082"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000698"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.04.009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4560"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810394717"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811401482"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810387965"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.05.011"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2015.05.011"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/02813432.2019.1569425"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021\u20109681(87)90171\u20108"},{"key":"e_1_2_11_48_1","unstructured":"NGreifer EAStuart.Choosing the causal estimand for propensity score analysis of observational studies arXiv Preprint posted online July 11 2023.https:\/\/doi.org\/10.48550\/arXiv.2106.10577"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab041"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq198"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16181"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16182"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16180"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16179"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010025\u201001536\u20107"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5547"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy120"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy201"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100814"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.017"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz129"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090536"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15912"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70558","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:26:22Z","timestamp":1785371182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/bcp.70558"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70558","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}